Genome Biologics
Genome Biologics is a German biotechnology company (founded 2016) that develops and provides human cardiac organoid-based screening and disease-modeling services for drug discovery, cardiotoxicity assessment and translational efficacy testing. The company operates an iPSC-derived, multicellular, vascularised and innervated cardiac organoid platform and offers CRO-style study packages, integrated multi-omics analytics, and AI-driven target and heterogeneity mapping tools. Reported laboratory locations include Frankfurt (Goethe University) and a presence within a Johnson & Johnson Innovation incubator. The company also describes workflows that translate AI-driven analytics into ex vivo and in vivo disease models and transgenesis in large animal models (minipigs) for preclinical validation.
Industries
Nr. of Employees
small (1-50)
Genome Biologics
Patents
Products
Ready-to-use human cardiac organoids (healthy and selected disease states)
Physiologically advanced, vascularised and multicellular organoids derived from iPSCs for use in preclinical screening and disease modeling.
TrueCardium®
An advanced human 3D cardiac organoid and engineered heart tissue system aligned with cardiac New Approach Methodology (NAM) platforms for translational target validation, disease modelling, and predictive safety assessment.
GENISYST
Advanced platform for modeling complex disease heterogeneity within TrueCardium organoids, enabling multiplexed analysis of genetic drivers, inflammatory pathways, and patient-stratified phenotypes.
Ready-to-use human cardiac organoids (healthy and selected disease states)
Physiologically advanced, vascularised and multicellular organoids derived from iPSCs for use in preclinical screening and disease modeling.
TrueCardium®
An advanced human 3D cardiac organoid and engineered heart tissue system aligned with cardiac New Approach Methodology (NAM) platforms for translational target validation, disease modelling, and predictive safety assessment.
GENISYST
Advanced platform for modeling complex disease heterogeneity within TrueCardium organoids, enabling multiplexed analysis of genetic drivers, inflammatory pathways, and patient-stratified phenotypes.
Services
Functional and biomarker-based screening workflows to detect contractile dysfunction, electrophysiologic instability and cardiac injury using organoid endpoints.
Multi-dose study designs integrating molecular and histological endpoints with structured reporting to support nonclinical regulatory submissions.
Custom and validated disease-state organoid studies (e.g., HFpEF, fibrosis, inflammation, mitochondrial dysfunction) for therapeutic efficacy testing and mechanistic investigation.
Combined transcriptomic, proteomic and metabolomic analytics applied to organoid studies for mechanism-of-action and biomarker discovery.
Provision of physiologically advanced, ready-to-use human cardiac organoids in healthy and selected disease states for partner integration into in-house workflows.
Low- to medium-throughput compound screening pipelines combining viability, contractility, electrophysiology and metabolic endpoints in organoid formats.
Functional and biomarker-based screening workflows to detect contractile dysfunction, electrophysiologic instability and cardiac injury using organoid endpoints.
Multi-dose study designs integrating molecular and histological endpoints with structured reporting to support nonclinical regulatory submissions.
Custom and validated disease-state organoid studies (e.g., HFpEF, fibrosis, inflammation, mitochondrial dysfunction) for therapeutic efficacy testing and mechanistic investigation.
Combined transcriptomic, proteomic and metabolomic analytics applied to organoid studies for mechanism-of-action and biomarker discovery.
Provision of physiologically advanced, ready-to-use human cardiac organoids in healthy and selected disease states for partner integration into in-house workflows.
Low- to medium-throughput compound screening pipelines combining viability, contractility, electrophysiology and metabolic endpoints in organoid formats.
Expertise Areas
- Cardiotoxicity screening and cardiac safety pharmacology
- Human cardiac disease modeling and organoid engineering
- iPSC differentiation and organoid maturation
- Multi-omics profiling and biomarker discovery
Key Technologies
- iPSC-derived 3D cardiac organoids
- Single-cell and bulk RNA sequencing
- Spatial transcriptomics
- Proteomics and phosphoproteomics
News & Updates
Krishnan J, et al. Study on metabolic pathway integration in cardiac hypertrophy published in Cell Metabolism.
Wagner JUG, et al. Report on increased toxicity of SARS-CoV-2 variants in cardiovascular cells published in European Heart Journal (conference abstract / supplement).
Bojkova D, et al. Experimental evidence of SARS-CoV-2 cytotoxicity in human cardiomyocytes published in Cardiovascular Research.
Trembinski et al. Study on a long non-coding RNA that enhances recovery after myocardial infarction published in Nature Communications.
Wagner J, et al. Analysis of intercellular communication in vascularized cardiac tissue models published in Journal of Molecular and Cellular Cardiology.
Rogg EM, et al. Cell-type specific analysis of miR-92a with implications for mechanism of action published in Circulation.
Krishnan J, et al. Study on metabolic pathway integration in cardiac hypertrophy published in Cell Metabolism.
Wagner JUG, et al. Report on increased toxicity of SARS-CoV-2 variants in cardiovascular cells published in European Heart Journal (conference abstract / supplement).
Bojkova D, et al. Experimental evidence of SARS-CoV-2 cytotoxicity in human cardiomyocytes published in Cardiovascular Research.
Trembinski et al. Study on a long non-coding RNA that enhances recovery after myocardial infarction published in Nature Communications.
Wagner J, et al. Analysis of intercellular communication in vascularized cardiac tissue models published in Journal of Molecular and Cellular Cardiology.
Rogg EM, et al. Cell-type specific analysis of miR-92a with implications for mechanism of action published in Circulation.